BioCentury | Mar 31, 2021
Product Development

Flagship’s Omega fuels RNA-encoded, genomic structure-targeting pipeline with $126M series C

Omega is pushing further into the white space of targeting 3-D genomic structures via a $126 million series C round, with a crossover syndicate joining founding investor Flagship Pioneering. Mahesh Karande, Omega Therapeutics Inc.’s president and...
BioCentury | Dec 11, 2020
Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

Research into biomolecular condensates is gaining momentum with Third Rock launching the third company in the past month that aims to tackle the emerging space. On Thursday, the firm launched Faze Medicines Inc. to develop therapeutics targeting the...
BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

Several recent publications highlighting host factors that modulate ACE2 expression point to possible new targets for COVID-19 therapies.  ACE2 and TMPRSS2 are the most common host targets of...
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

The Phase II miss of the first tau antibody to reach that stage continue the tradition in Alzheimer’s disease of bad news with hard-to-interpret ramifications for the target. At a minimum, the data call into...
BioCentury | Jun 26, 2020
Distillery Therapeutics

Blocking cGAS for colitis

...Medicine, Nanjing, China email: CONTACT: Lue Dai, Roche Innovation Center Shanghai, Shanghai, China email:
BioCentury | Jun 11, 2020

Prism’s peptide mimetic platform finds second discovery partner

...disrupt interactions between intrinsically disordered proteins, an emerging class of targets. Prism President and CEO Dai...
BioCentury | May 13, 2020
Emerging Company Profile

QurAlis taking three ALS programs toward clinic with $42M series A

After launching with a modest seed round in 2018, neurology company QurAlis is driving toward the clinic with a $42 million series A round to fund development of three therapies to treat amyotrophic lateral sclerosis...
BioCentury | May 1, 2020
Distillery Therapeutics

Blocking necroptosis to treat inflammatory bowel disease

...CATEGORY: Autoimmune disease INDICATION: Inflammatory bowel disease (IBD) Inhibiting necroptosis by targeting RIPK3, MLKL or ZBP1...
...had lower levels of SETDB1 mRNA and protein, as well as lower protein levels of ZBP1...
...survival. TARGET/MARKER/PATHWAY: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); mixed-lineage kinase domain-like (MLKL); Z-DNA binding protein 1 (ZBP1; DAI; DLM1...
BioCentury | Apr 30, 2020
Distillery Therapeutics

Heparan sulfate for prevention of acetaminophen-induced acute liver failure

DISEASE CATEGORY: Hepatic INDICATION: Liver failure Inhibiting HMGB1, a DNA-binding protein, with a polysaccharide composed of 18 heparan sulfate units could prevent acute liver failure due to acetaminophen overdose. Patients with acetaminophen-induced acute liver failure...
BioCentury | Aug 12, 2019
Company News

Aug. 12 Company Quick Takes: Jazz buying Cavion; plus Boehringer, AC Immune, Oncologie

Jazz gains essential tremor asset via Cavion takeout Jazz Pharmaceuticals plc (NASDAQ:JAZZ) acquired Cavion Inc. for $52.5 million up front and up to $260 million in clinical, regulatory and sales milestones in a deal that...
Items per page:
1 - 10 of 352